Singapore markets closed

Erasca, Inc. (ERAS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.0600+0.0800 (+4.04%)
At close: 04:00PM EDT
2.3600 +0.30 (+14.56%)
Pre-market: 06:44AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.9800
Open1.9900
Bid2.0300 x 100
Ask2.0600 x 100
Day's range1.9626 - 2.0800
52-week range1.5100 - 3.3750
Volume280,210
Avg. volume778,688
Market cap311.239M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.8300
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.50
  • GlobeNewswire

    Erasca Announces $45 Million Oversubscribed Private Placement Financing

    Funding from new and existing investors extends anticipated cash runway into H2 2026SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) (“Erasca”), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 21,844,660 shares o

  • GlobeNewswire

    Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

    Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 a

  • GlobeNewswire

    Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

    Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected between Q2-Q4 2024 Initiation of pivotal SEACRAFT-2 in NRASm melanoma expected in H1 2024 SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients wi